Phase 0 trial of CBD in recurrent glioblastoma patients

2024-513357-74-01 Protocol CBD in GBM Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 4 Aug 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol CBD in GBM

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 7
Countries 1
Sites 1

Glioblastoma

Key facts

Sponsor
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
4 Aug 2025 → ongoing
Decision date (initial)
2024-10-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glioblastoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Sponsor organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Address
Dr. Molewaterplein 40
City
Rotterdam
Postcode
3015 GD
Country
Netherlands

Scientific contact point

Organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Contact name
Martin van den Bent

Public contact point

Organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Contact name
Martin van den Bent

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 7 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neurology, Dr. Molewaterplein 40, 3015 GD, Rotterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-08-04 2025-10-08

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-26 Netherlands Acceptable
2024-10-22
2024-10-22
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-07-30 Netherlands Acceptable
2024-10-22
2025-07-30